Additionally, the vector AdV-D24 alone or in combination with anti PD-1 antibody also showed anticancer efficacy in comparison to anti-PD1 antibody alone, where no effect was detected thus suggesting that the B16V melanoma seems to be refractory to the ICI therapy (261; 244; 445 mm3, respectively for AdV-D24, AdV-D24 plus anti PD-1 and PD-1 alone). This evidence concerns the gene PDCD1 and melanoma.